TRACON to Report Third Quarter 2015 Company Highlights and Financial Results on November 3, 2015

SAN DIEGO, Oct. 27, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its third quarter 2015 financial and operating results after the close of U.S. financial markets on Tuesday, November 3, 2015. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.

Conference call and webcast:
Date:November 3, 2015
Time:4:30 pm Eastern Standard Time (1:30 pm Pacific Standard Time)
Dial-in:(855) 779-9066 (Domestic) or (631) 485-4859 (International)
Via web:www.traconpharma.com; “Events and Presentation” section within the “Investors” section

A replay of the webcast will be available for 60 days on the website.


TRACON develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. TRACON’s pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 clogan@traconpharma.com Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 Andrew@lifesciadvisors.com

Source:TRACON Pharmaceuticals, Inc.